Literature DB >> 15030397

Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells.

Teresa Iuvone1, Giuseppe Esposito, Ramona Esposito, Rita Santamaria, Massimo Di Rosa, Angelo A Izzo.   

Abstract

Abstract Alzheimer's disease is widely held to be associated with oxidative stress due, in part, to the membrane action of beta-amyloid peptide aggregates. Here, we studied the effect of cannabidiol, a major non-psychoactive component of the marijuana plant (Cannabis sativa) on beta-amyloid peptide-induced toxicity in cultured rat pheocromocytoma PC12 cells. Following exposure of cells to beta-amyloid peptide (1 micro g/mL), a marked reduction in cell survival was observed. This effect was associated with increased reactive oxygen species (ROS) production and lipid peroxidation, as well as caspase 3 (a key enzyme in the apoptosis cell-signalling cascade) appearance, DNA fragmentation and increased intracellular calcium. Treatment of the cells with cannabidiol (10(-7)-10(-4)m) prior to beta-amyloid peptide exposure significantly elevated cell survival while it decreased ROS production, lipid peroxidation, caspase 3 levels, DNA fragmentation and intracellular calcium. Our results indicate that cannabidiol exerts a combination of neuroprotective, anti-oxidative and anti-apoptotic effects against beta-amyloid peptide toxicity, and that inhibition of caspase 3 appearance from its inactive precursor, pro-caspase 3, by cannabidiol is involved in the signalling pathway for this neuroprotection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15030397     DOI: 10.1111/j.1471-4159.2003.02327.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  72 in total

1.  Endocannabinoids prevent β-amyloid-mediated lysosomal destabilization in cultured neurons.

Authors:  Janis Noonan; Riffat Tanveer; Allan Klompas; Aoife Gowran; Joanne McKiernan; Veronica A Campbell
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

Review 2.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors:  Javier Fernández-Ruiz; Onintza Sagredo; M Ruth Pazos; Concepción García; Roger Pertwee; Raphael Mechoulam; José Martínez-Orgado
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

3.  The endocannabinoid system and Alzheimer's disease.

Authors:  Cristina Benito; Estefanía Núñez; María Ruth Pazos; Rosa María Tolón; Julián Romero
Journal:  Mol Neurobiol       Date:  2007-09-05       Impact factor: 5.590

4.  Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression.

Authors:  G Esposito; C Scuderi; C Savani; L Steardo; D De Filippis; P Cottone; T Iuvone; V Cuomo; L Steardo
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

Review 5.  Cyclooxygenase-2 in synaptic signaling.

Authors:  Hongwei Yang; Chu Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 6.  Targeting the endocannabinoid system in Alzheimer's disease.

Authors:  Jeremy Koppel; Peter Davies
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

7.  Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro.

Authors:  Emelie Janefjord; Jesper L V Mååg; Benjamin S Harvey; Scott D Smid
Journal:  Cell Mol Neurobiol       Date:  2013-09-13       Impact factor: 5.046

8.  Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death.

Authors:  Hao Pan; Partha Mukhopadhyay; Mohanraj Rajesh; Vivek Patel; Bani Mukhopadhyay; Bin Gao; György Haskó; Pál Pacher
Journal:  J Pharmacol Exp Ther       Date:  2008-12-12       Impact factor: 4.030

Review 9.  Alzheimer's disease; taking the edge off with cannabinoids?

Authors:  V A Campbell; A Gowran
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 10.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.